How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comAn Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients With Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas
Description:
Traditional imaging techniques for insulinomas have a low detection rate. This study aims to evaluate the safety, internal radiation dosimetry, and targeted imaging capability of the novel GLP1R imaging agent, 68Ga-DOTA-SEMA, in patients with GLP1R-positive insulinomas.
Sponsor:
The Affiliated Hospital of Southwest Medical University
Phase:
N/A
Contacts:
Xie Yangxy114330@163.com
15183071089
Government Study Link:
NCT06759740 - Click here to see study onClinicalTrials.gov
68Ga-DOTA-SEMA
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- Glucagon-Like Peptide-1 Receptor (GLP1R)
Chelator: DOTA
Share your feedback
Help us improve your experience